Klaria Q2 2026: Net Sales at Zero, Losses Decrease
Klaria Pharmaceutics AB reported its second quarter 2026 results, showing net sales of 0.0 MSEK. The company's net loss for the period decreased compared to the previous year.
Klaria Pharmaceutics AB has released its interim report for the second quarter of 2026, covering the period from April 1 to June 30.
The company reported net sales of 0.0 MSEK for the quarter, a figure consistent with the same period in the prior year.
Research and development expenses decreased significantly, amounting to 4.4 MSEK compared to 7.1 MSEK in the second quarter of 2025. Despite this reduction in R&D spending, the net loss for the quarter was -12.9 MSEK, an improvement from the -20.1 MSEK loss reported in the previous year.
Operating activities generated a negative cash flow of -14.8 MSEK. As of June 30, 2026, Klaria's liquid assets stood at 8.5 MSEK, while the group's equity was -33.0 MSEK.